Curaleaf Keeps Aurora Takeover Bid Alive After Organigram Deal

Curaleaf Holdings said in a November 3, 2026 statement that its enhanced takeover offer for Aurora Cannabis (ACB ) remains outstanding after Aurora announced an alternative transaction with Organigram Global (OGI ), keeping its bid active while it studies the competing agreement.

Curaleaf is awaiting disclosure of any break fee, the future management and board composition, and any investor rights being granted to BAT, a wholly owned indirect subsidiary of British American Tobacco. It also criticized Aurora and Organigram for not saying whether their transaction is dilutive or accretive to shareholders. The bidder characterized its own offer as better value, with a superior combined business, a stronger capital-markets profile, greater certainty and speed to close, and greater anticipated synergies.

Diligence Access Remains the Central Dispute

Curaleaf alleged that Aurora’s board granted Organigram due diligence access while refusing Curaleaf access and direct engagement, and that the refusal blocks any chance of an enhanced Curaleaf bid and constitutes gross dereliction of fiduciary duties.

Curaleaf characterized Organigram as significantly smaller, underperforming and less liquid, burdened by a looming share overhang, past and forthcoming shareholder dilution and weak cash generation, and criticized BAT’s cannabis investment track record.

The enhanced proposal Curaleaf announced on October 5, 2026, and subsequently amended on October 6, carried total implied consideration of US$5.00 per Aurora share: 0.4013 Curaleaf shares plus US$1.00 in cash, based on Curaleaf’s October 2, 2026 closing price. The maximum consideration cap was raised to US$6.00 per Aurora share. Curaleaf said a combination would span 17 countries, with more than US$1.5 billion in last-twelve-month revenue and at least US$40 million in expected annual cost synergies.

Organigram and Aurora announced their arrangement on November 3, 2026, with Organigram to acquire all issued and outstanding Aurora common shares for C$7.80 each, valuing Aurora at approximately C$561 million on a fully diluted equity-value basis. Aurora shareholders may elect cash, Organigram shares or a combination, subject to proration. The companies say the consideration represents a 21% premium to the implied value of Curaleaf’s amended bid as of November 2, 2026. The arrangement requires specified shareholder approvals from both companies, regulatory approvals and approval of the Supreme Court of British Columbia. Shareholder meetings are expected in December 2026, with completion expected in January 2027, subject to conditions.

BAT Financing and Rights Remain in Focus

Some of the BAT information Curaleaf requested is addressed in that transaction announcement. Concurrent with closing, BAT is to acquire 141.0 million Organigram shares at C$1.33 each, providing C$187.5 million in gross proceeds to finance part of the cash consideration and transaction expenses.

BAT’s existing investor-rights agreement gives it the right to nominate up to 30% of Organigram’s board, subject to ownership thresholds, along with pre-emptive, top-up and customary registration rights. Organigram and BAT intend to amend that agreement at closing to clarify the pre-emptive and top-up rights, among other provisions. The amendment’s terms remain to be negotiated before the concurrent closing of the private placement and Aurora transaction.

Curaleaf’s response keeps its offer before Aurora shareholders as the Organigram arrangement moves toward December votes. The immediate pressure points are the unfinished BAT rights amendment and Curaleaf’s demand for diligence access, both of which bear on its argument that its own proposal would deliver the stronger combination.